Related Experiment Video
Updated: Jan 12, 2026
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
Phenoxybenzamine: Old Wine in a Bright New Bottle-Taming the wild side of Phenoxybenzamine
R Benedict Raj1, Srinath Reddy Narahari1, Vasudev Vemala1
1Department of Paediatric Cardiology and Cardiac Surgery, Children's Heart Institute, Aster Ramesh Hospitals, Vijayawada, Andhra Pradesh, India.
Background:
Phenoxybenzamine (PBZ), a long-acting α-blocker, was once widely used in pediatric cardiac surgeries but fell out of favor due to concerns about systemic hypotension. In the context of developing countries and resource-limited settings, PBZ may offer a cost-effective and safe alternative when used in a controlled protocol.
Objective:
To evaluate the safety and efficacy of a PBZ-based vasoplegic strategy during cardiopulmonary bypass (CPB) in pediatric open-heart surgeries.
Materials And Methods:
A prospective observational study was conducted between 2015 and 2020 at a tertiary care cardiac center. A total of 520 pediatric patients undergoing open-heart surgery with CPB received PBZ as the primary vasodilator in combination with low-dose adrenaline. Hemodynamic data, ICU outcomes, and incidence of postoperative complications were analyzed.
Results:
The protocol achieved stable intraoperative perfusion without the need for additional vasopressors. Most patients were extubated on the same day, and the incidence of pulmonary arterial hypertension crisis was negligible (one case). Mortality was limited to 2.7%, and postoperative hypotension was effectively managed with fluid and adrenaline support.
Conclusion:
PBZ, when used in a structured intraoperative protocol, offers a safe, economical, and effective strategy for pediatric cardiac surgeries, especially in settings with limited access to newer vasoplegic agents.
More Related Videos
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
11:27The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System
Published on: April 25, 2012
Related Concept Videos
01:26Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
01:21Drugs Affecting Neurotransmitter Release or Uptake
01:30Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...